OTC : NOXOF

Noxopharm Limited

$0.045 USD

$0 (0.0%)

Volume
2.3K
Average Volume
1.15K
Market Capitalization
$14.78M
P/E Ratio
-4.15
Dividend Yield
0.00%
Price Target
Year High
$0.05
Year Low
$0.05
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.81
Company Overview

OTC

Gisela Mautner

Biotechnology

Healthcare

NOXOF

N/A

AU

USD

https://www.noxopharm.com

61 2 9144 2223

N/A

N/A

Liquidity Metrics

-3.77

0.81

0.81

0.02

0.00

Sales & Valuation

$2.4M

14.40

-20.22

-3.29

-0.02

Profitability

-$0.0122

-$3.58M

-329.78%

-433.76%

2509.60%

-115.62%

P/E Metrics

-4.15

0.04

0.04

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Financial Health Scores

-8.13

3/9

$3.52M

$6.78M

$1.29M

-$9.92M

Key Metrics (TTM)

$29.35M

17.63

-4.78

0.81

2509.60%

-149.71%

-22.91%

-28.87%

932 days

Company Executives
Name Title
Olivier Laczka Chief Scientific Officer of Inflammation
John Wilkinson Chief Scientific Officer of Oncology
Jeanette Bell Chief Operating Officer
Gisela Mautner Chief Executive Officer, Executive MD & Director
David James Franks Company Secretary
Shawn Van Boheemen Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About Noxopharm Limited (OTC:NOXOF) Stock

Noxopharm Limited, a pharmaceutical company, is focused on developing therapeutic solutions for a range of solid tumor cancers and septic shock, catering to both Australian and international markets. Its primary asset, Veyonda, is currently being developed as an adjuvant therapy, intended to complement chemotherapy and radiotherapy in the treatment of late-stage cancers. The company's robust pipeline includes several programs: The DARRT program, currently in Phase 1b/2a, targets metastatic castration-resistant prostate cancer and other solid tumor types. LuPIN investigates a combined therapy of Veyonda with 177Lu-PSMA-617 for managing late-stage prostate cancer. The IONIC program explores Veyonda in combination with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, for various solid tum ... or indications. Its Chemotherapy Enhancement Program (CEP) utilizes Veyonda alongside carboplatin to treat refractory solid tumors found in the breast, head and neck, lung, prostate, and ovaries. Beyond oncology, Noxopharm is advancing the NOXCOVID Program, a dose escalation and expansion study of NOX66, aimed at treating COVID-19 infections. Additionally, the company is pursuing early-stage programs for pancreatic cancer and glioblastoma. Noxopharm Limited has established a collaboration with the Hudson Institute of Medical Research and The Australian National University to conduct research and development into therapeutic drugs for inflammatory disorders. Founded in 2015, the company is based in Chatswood, Australia.

Frequently Asked Questions

What is the current Noxopharm Limited (NOXOF) stock price?

Noxopharm Limited(OTC:NOXOF) stock price is $0.045 in the last trading session. During the trading session, NOXOF stock reached the peak price of $0.045 while $0.045 was the lowest point it dropped to. The percentage change in NOXOF stock occurred in the recent session was 0.0% while the dollar amount for the price change in NOXOF stock was $0.

NOXOF's industry and sector of operation?

The OTC listed NOXOF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of NOXOF?

Olivier Laczka | Chief Scientific Officer of Inflammation
John Wilkinson | Chief Scientific Officer of Oncology
Jeanette Bell | Chief Operating Officer
Gisela Mautner | Chief Executive Officer, Executive MD & Director
David James Franks | Company Secretary

How many employees does NOXOF have?

Number of NOXOF employees currently stands at None. NOXOF operates from Tower A, The Zenith, Chatswood, NSW 2067, AU.

Link for NOXOF official website?

Official Website of NOXOF is: https://www.noxopharm.com

How do I contact NOXOF?

NOXOF could be contacted at phone #61 2 9144 2223 and can also be accessed through its website. NOXOF operates from Tower A, The Zenith, Chatswood, NSW 2067, AU.

How many shares of NOXOF are traded daily?

The average number of NOXOF shares traded daily for last 3 months was 1.15K.

What is the market cap of NOXOF currently?

The market value of NOXOF currently stands at $14.78M with its latest stock price at $0.045